Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1967 1
1968 3
1969 1
1972 1
1976 1
1978 1
1981 3
1982 1
1983 1
1984 3
1988 2
1989 2
1990 4
1991 2
1992 2
1993 1
1995 8
1996 2
1997 2
1999 2
2000 3
2001 3
2002 7
2003 8
2004 6
2005 8
2006 6
2007 6
2008 20
2009 16
2010 29
2011 27
2012 27
2013 29
2014 47
2015 42
2016 41
2017 43
2018 49
2019 48
2020 76
2021 97
2022 64
2023 61
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

747 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of infections caused by multidrug-resistant Gram-negative bacilli: a practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
Meschiari M, Asquier-Khati A, Tiseo G, Luque-Paz D, Murri R, Boutoille D, Falcone M, Mussini C, Tattevin P; Italian Society of Infectious and Tropical Diseases (SIMIT), and the French Society of Infectious Diseases (SPILF). Meschiari M, et al. Among authors: mussini c. Int J Antimicrob Agents. 2024 Apr 28:107186. doi: 10.1016/j.ijantimicag.2024.107186. Online ahead of print. Int J Antimicrob Agents. 2024. PMID: 38688353
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Tusch E, et al. Clin Infect Dis. 2024 Apr 26:ciae228. doi: 10.1093/cid/ciae228. Online ahead of print. Clin Infect Dis. 2024. PMID: 38663013
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM, Polizzotto MN, Maltez F, Rauch A, Grabmeier-Pfistershammer K, Wit F, De Wit S, Castagna A, d'Arminio Monforte A, Mussini C, Wasmuth JC, Fontas E, Abela I, Sarcletti M, Bansi-Matharu L, Jaschinski N, Peters L, Hosein SR, Vannappagari V, Cohen C, Bissio E, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group. Byonanebye DM, et al. Among authors: mussini c. Lancet HIV. 2024 May;11(5):e321-e332. doi: 10.1016/S2352-3018(23)00328-4. Epub 2024 Apr 12. Lancet HIV. 2024. PMID: 38621392
The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV.
Guaraldi G, Milic J, Renzetti S, Motta F, Cinque F, Bischoff J, Desilani A, Conti J, Medioli F, Del Monte M, Kablawi D, Elgretli W, Calza S, Mussini C, Rockstroh JK, Sebastiani G. Guaraldi G, et al. Among authors: mussini c. AIDS. 2024 Apr 10. doi: 10.1097/QAD.0000000000003903. Online ahead of print. AIDS. 2024. PMID: 38597416
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. Among authors: mussini c. J Antimicrob Chemother. 2024 Apr 6:dkae081. doi: 10.1093/jac/dkae081. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38581349
Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia.
Cozzi-Lepri A, Borghi V, Rotundo S, Mariani B, Ferrari A, Del Borgo C, Bai F, Colletti P, Miraglia P, Torti C, Cattelan AM, Cenderello G, Berruti M, Tascini C, Parruti G, Coladonato S, Gori A, Marchetti G, Lichtner M, Coppola L, Sorace C, D'Abramo A, Mazzotta V, Guaraldi G, Franceschini E, Meschiari M, Sarmati L, Antinori A, Nicastri E, Mussini C. Cozzi-Lepri A, et al. Among authors: mussini c. Front Med (Lausanne). 2024 Mar 11;11:1293431. doi: 10.3389/fmed.2024.1293431. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38529120 Free PMC article.
Advances and Challenges in Sepsis Management: Modern Tools and Future Directions.
Santacroce E, D'Angerio M, Ciobanu AL, Masini L, Lo Tartaro D, Coloretti I, Busani S, Rubio I, Meschiari M, Franceschini E, Mussini C, Girardis M, Gibellini L, Cossarizza A, De Biasi S. Santacroce E, et al. Among authors: mussini c. Cells. 2024 Mar 2;13(5):439. doi: 10.3390/cells13050439. Cells. 2024. PMID: 38474403 Free PMC article. Review.
Persistent poor clinical outcomes of people living with HIV presenting with AIDS and late HIV diagnosis - results from the ICONA cohort in Italy, 2009-2022.
Mondi A, Cozzi-Lepri A, Tavelli A, Cingolani A, Giacomelli A, Orofino G, De Girolamo G, Pinnetti C, Gori A, Saracino A, Bandera A, Marchetti G, Girardi E, Mussini C, d'Arminio Monforte A, Antinori A; ICONA Foundation Study Group. Mondi A, et al. Among authors: mussini c. Int J Infect Dis. 2024 May;142:106995. doi: 10.1016/j.ijid.2024.106995. Epub 2024 Mar 6. Int J Infect Dis. 2024. PMID: 38458423 Free article.
Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience.
Meschiari M, Faltoni M, Kaleci S, Tassoni G, Orlando G, Franceschini E, Burastero G, Bedini A, Serio L, Biagioni E, Melegari G, Venturelli C, Sarti M, Bertellini E, Girardis M, Mussini C. Meschiari M, et al. Among authors: mussini c. Int J Antimicrob Agents. 2024 May;63(5):107134. doi: 10.1016/j.ijantimicag.2024.107134. Epub 2024 Mar 5. Int J Antimicrob Agents. 2024. PMID: 38453094
747 results